Biotechnology News and Research

RSS

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Micromet prices public offering at $7.00 per share

Micromet, Inc. announced today the pricing of an underwritten public offering of 10 million shares of common stock at a public offering price of $7.00 per share. The Company has granted the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being sold by Micromet. The closing of the offering is expected to take place on March 17, 2010, subject to the satisfaction of customary closing conditions.

12 Mar 2010

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

From Baxter International Inc. 12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

Microchip Biotechnologies renamed as IntegenX

Microchip Biotechnologies, a maker of automated microscale biotech laboratory systems, today announced that it has changed its business name to IntegenX. The new name articulates the company's focus on integrating sample preparation and analysis technologies into complete products that address generic problems shared by life science and biotechnology research laboratories worldwide.

12 Mar 2010

Sigma-Aldrich announces global licensing agreement with CSIRO for RAFT agents

Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.

12 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

NeoMed invests in CytoCore

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that NeoMed has made an investment in CytoCore Inc.

11 Mar 2010

Illumina sequences DNA of American actress Glenn Close

Illumina, Inc. today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage.

From Illumina, Inc. 11 Mar 2010

Biotechnology News and Research

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

StockPreacher.com announces investment report featuring Generex Biotechnology

BeaconEquity.com announces investment report featuring NexMed

Micromet prices public offering at $7.00 per share

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

Genentech announces topline results from Phase III trial of Avastin

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Microchip Biotechnologies renamed as IntegenX

Sigma-Aldrich announces global licensing agreement with CSIRO for RAFT agents

TTI granted exclusive worldwide rights to commercialize two immunology programs

NeoMed invests in CytoCore

Illumina sequences DNA of American actress Glenn Close

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News